Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Galapagos NV ADR (NQ: GLPG ) 26.93 -0.72 (-2.62%) Streaming Delayed Price Updated: 3:29 PM EDT, Jul 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 63,937 Open 27.15 Bid (Size) 26.90 (3) Ask (Size) 26.93 (2) Prev. Close 27.65 Today's Range 26.74 - 27.30 52wk Range 24.78 - 44.25 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News GLPG Stock Earnings: Galapagos Beats EPS, Misses Revenue for Q1 2024 June 25, 2024 GLPG stock results show that Galapagos beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications May 30, 2024 Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell... Via Newsfile Performance YTD -34.87% -34.87% 1 Month +7.66% +7.66% 3 Month -5.36% -5.36% 6 Month -28.90% -28.90% 1 Year -36.42% -36.42% More News Read More Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst April 01, 2024 Via Benzinga Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline February 22, 2024 From Frontier Medicines Via GlobeNewswire 8 Analysts Have This to Say About Galapagos July 17, 2023 Via Benzinga Where Galapagos Stands With Analysts June 12, 2023 Via Benzinga JP Morgan Maintains Neutral Rating for Galapagos: Here's What You Need To Know May 31, 2023 Via Benzinga Earnings Outlook For Galapagos May 03, 2023 Via Benzinga European Drugmaker Galapagos Collaborates With Biotech BridGene Biosciences To Develop Cancer Treatments January 03, 2024 Via Benzinga GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q3 2023 December 13, 2023 Via InvestorPlace Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023 May 08, 2023 Via Benzinga BigCommerce, ContextLogic And Other Big Stocks Moving Lower In Friday's Pre-Market Session February 24, 2023 Via Benzinga Earnings Preview For Galapagos February 23, 2023 Via Benzinga Where Galapagos Stands With Analysts November 07, 2022 Via Benzinga Galapagos' Blood Cancer Candidate Shows 100% Objective Response Rate In Relapsed/Refractory Patients February 10, 2023 Via Benzinga Why Galapagos Stock Is Falling Today February 09, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For January 23, 2023 January 23, 2023 Via Benzinga Where Galapagos Stands With Analysts September 09, 2022 Via Benzinga Twitter Rolls Out 'Blue For Business,' Visa Pitches Auto-Payments On Ethereum Blockchain, Justin Bieber Slams H&M: Today's Top Stories December 20, 2022 Via Benzinga On A Mission As Top European Player, Galapagos Looks For Acquisition Targets December 20, 2022 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For November 7, 2022 November 07, 2022 Via Benzinga After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns October 31, 2022 Via Benzinga Expert Ratings for Galapagos October 13, 2022 Via Benzinga 3 Biotech Stocks to Sell in October September 29, 2022 Via InvestorPlace Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 September 09, 2022 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
